LGND - Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Story updates
11:01:42 AM UTC
SquawkNews
Ryjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patientsLigand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and AfricaJUPITER, Fla., Sept. 2…
11:02:11 AM UTC
SquawkNews
Ligand will pay $23M to acquire a tiered low-double-digit to high-teens royalty and certain milestones on Santen’s Ryjunea sales in EMEA from Sydnexis. Sydnexis retains Ryjunea rights in the U.S. and other non-Santen territories.Material DetailsContext by AI AnalystThis adds another commercial roya…